Join
Live feed
·
PRReleasevia Quantisnow
I-MAB logo

I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

ByQuantisnow·Wall Street's wire, on your screen.
IMAB· I-MAB
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMAB (I-MAB) and more on Quantisnow.